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Abstract
AIM: To investigate thrombotic microangiopathy (TMA) 
in liver transplantion, because TMA is an infrequent but 
life-threatening complication in the transplantation field. 
METHODS: A total of 206 patients who underwent 
living-donor liver transplantation (LDLT) were evaluated, 
and the TMA-like disorder (TMALD) occurred in seven 
recipients. 
RESULTS: These TMALD recipients showed poor 
outcomes in comparison with other 199 recipients. Al-
though two TMALD recipients successfully recovered, 
the other five recipients finally died despite intensive 
treatments including repeated plasma exchange (PE) 
and re-transplantation. Histopathological analysis of liver 
biopsies after LDLT revealed obvious differences accord-
ing to the outcomes. Qualitative analysis of antibodies 
against a disintegrin-like domain and metalloproteinase 
with thrombospondin type 1 motifs (ADAMTS-13) were 
negative in all patients. The fragmentation of red cells, 
the microhemorrhagic macules and the platelet counts 
were early markers for the suspicion of TMALD after 
LDLT. Although the absolute values of von Willebrand 
factor (vWF) and ADAMTS-13 did not necessarily reflect 
TMALD, the vWF/ADAMTS-13 ratio had a clear diag-
nostic value in all cases. The establishment of adequate 
treatments for TMALD, such as PE for ADAMTS-13 re-
plenishment or treatments against inhibitory antibodies, 
must be decided according to each case.
CONCLUSION: The optimal induction of adequate ther-
apies based on early recognition of TMALD by the reli-
able markers may confer a large advantage for TMALD 
after LDLT.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
Thrombotic microangiopathy (TMA) is a microvascular 
occlusive disorder induced by facilitation of  endothelial 
damage and primary platelet (PLT) aggregation[1]. Cur-
rently, the concept of  TMA encompasses two previous 
entries, i.e., thrombotic thrombocytopenic purpura and 
hemolytic uremic syndrome[2]. Although the specific 
pathophysiological mechanism is still not understood, many 
investigators have focused on a disintegrin-like domain 
and metalloproteinase with thrombospondin type 1 mo-
tifs (ADAMTS)-13 as a metalloproteinase that specially 
cleaves the multimeric von Willebrand factor (vWF)[3-5]. 
The vWF is an essential factor for the adhesion/aggrega-
tion of  circulating PLTs associated with high shear stress-
es[6,7]. Following the identification of  ADAMTS-13 in 
2001[3-5], some investigators suggested that a deficiency of  
ADAMTS-13 activity[3,8] and/or inhibitory autoantibodies 
against ADAMTS-13[2,9] may cause TMA via a pathway in 
which unusually large vWF multimers elevate the shear 
stress and lead to excessive PLT clumping[6,7,10]. As a con-
sequence, PLTs would be consumed in TMA patients, and 
finally result in organ failure because of  microvascular oc-
clusion.
Clinically, TMA patients develop thrombocytopenia 
accompanied by hemolytic anemia and show a hemor-
rhagic tendency[1,2,11]. The TMA is clinically defined as 
thrombocytopenia and microangiopathic hemolytic ane-
mia with no apparent alternative explanations[1,12,13]. The 
diagnostic criteria for TMA are defined as follows[1,2,14,15]: 
(1) the presence of  thrombocytopenia (PLT count < 5.0 
× 104/mm3) or the progressive decline in PLT counts (de-
crease of  > 3.0 × 104/mm3 within 24 h); (2) microangio-
pathic hemolytic anemia [hemoglobin (HB) < 8.0 g/dL]; 
(3) sharply elevated levels of  serum lactate dehydrogenase 
(LDH) (typically > 500 IU/L); (4) the presence of  frac-
tionated erythrocytes in a blood smear; and  (5) severe de-
ficiency in ADAMTS-13 activity (< 5% in normal plasma) 
or prevalence of  ADAMTS-13-specific antibodies (Abs) 
categorized as immunoglobulin G (IgG) isotypes.
TMA is well known as a fatal complication after trans-
plantation, and its frequencies are documented to be 6% 
after bone marrow transplantation[16] and 3%-5% after 
solid-organ transplantation[17,18]. The first case of  TMA in 
the liver transplantation (LT) field was reported in 1984[19], 
and thereafter some researchers have reported that the 
frequency of  TMA after LT is 3.8%-5.0%[2,14].  Repeated 
plasma exchange (PE)/exchange transfusion (ET) is 
considered to be the standard therapy for TMA from the 
viewpoint of  the replenishment of  ADAMTS-13 and the 
depletion of  inhibitory Abs[13,15,20-22]. To date, a total of  
739 pediatric and 669 adult LTs have been performed in 
our institution. Although we have no experience of  cases 
that completely fulfilled the TMA criteria described above, 
seven cases were retrospectively considered to be TMA-
like disorder (TMALD) after living-donor liver transplan-
tation (LDLT). Here, we focused on post-LDLT TMA 
cases and present our results for TMALD patients. The 
pathophysiological basis, the early marker for the recogni-
tion of  TMALD, the reliable factors for diagnosis and 
further clinical strategies are discussed in the LDLT field.
MATERIALS AND METHODS
Patients
A total of  155 adult and 51 pediatric recipients who 
underwent LDLT at Kyoto University Hospital from 
April 2006 to March 2009 were evaluated in this study. 
Seven patients (five adults and two pediatric recipients) 
showed thrombocytopenia and microangiopathic hemolytic 
anemia with no apparent alternative causes. They were 
given the intensive TMALD treatments.
These seven patients comprised one male and six fe-
males, and their age range was 0.8-65.2 years. The primary 
diseases for LDLT included two cases each of  primary 
biliary cirrhosis and liver cirrhosis caused by hepatitis C 
virus (HCV), and one case each of  liver cirrhosis caused 
by autoimmune hepatitis, biliary atresia (post-Kasai’s por-
toenterostomy) and fulminant hepatic failure (etiology 
unknown). The United Network for Organ Sharing sta-
tuses were estimated to be four cases of  ⅡA, two of  ⅡB 
and one of  Ⅰ. The mean Child-Pugh score was 12.0 ± 1.7 
points (range, 10-14 points). The mean score of  the mod-
el for end-stage liver disease (MELD) or pediatric end-
stage liver disease (PELD) was 23.7 ± 8.8 points (range, 
17-41 points). The ABO blood groups were characterized 
as three cases each of  identical and incompatible and 
one case of  compatible. The donor relationships were 
four spouses, one grandmother, one father and one son. 
     The protocol of  the study was approved by the Ethics 
Review Committee for Clinical Studies of  Kyoto Univer-
sity Graduate School of  Medicine.
Operation
There were three left-lobe grafts, two extended lateral-seg-
ment grafts and one right-lobe graft without the middle 
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red cells (FRC) and microhemorrhagic macules (MHMs) 
were checked, and temporal changes in the counts or 
levels of  PLTs, HB, LDH, prothrombin time-international 
normalized ratio (PT-INR) and total bilirubin (T-BIL) 
were estimated.
The values for vWF and ADAMTS-13 were measured 
by enzyme-linked immunosorbent assays, and subsequently 
used to calculate the vWF/ADAMTS-13 ratio. Quantita-
tive determination of  inhibitory IgG (anti-ADAMTS-13 
Abs) was performed by the Bethesda method (the detec-
tion limit was 0.5 Bethesda units/mL). 
Normal ranges of  vWF, ADAMTS-13 and the vWF/
ADAMTS-13 ratio were calculated in a control group, with 
10% rejection region. A control group was composed of  
54 healthy volunteers (26 males and 29 females). Normal 
values of  vWF, ADAMTS-13 and the vWF/ADAMTS-13 
ratio were 60%-170%, 70%-120%, and 0.51-2.43, respec-
tively. The anti-ADAMTS-13 Abs were non-existent in 
healthy individuals (under the detection limit). 
The definition of TMALD
We still do not have any experience of  patients who 
strictly fulfilled all of  the TMA criteria. In this study, 
TMALD was defined as the LDLT recipients who ful-
filled the diagnostic criteria of  TMA without the abso-
lute value of  ADAMTS-13 activity or the presence of  
ADAMTS-13-specific Abs.
The risk factors for LT outcomes
Previous investigators have documented the important 
factors for LT outcomes, such as recipient age, disease, 
donor age, MELD/PELD score, ABO incompatibility, 
lymphocyte cross-match, cold ischemic time, operative time, 
blood loss, graft-recipient weight ratio, the type/number 
of  anastomosis and conventional liver function test at 
early postoperative period[23,25-33]. There were no statisti-
cal differences between the 2 groups in each risk factor 
for LDLT outcomes, respectively.
Histopathological analysis
A protocol liver needle biopsy (LNB) is not employed 
in our institution. However, all cases underwent an LNB 
before and after the treatments for TMALD, except for 
one case in which an LNB could not be performed be-
cause of  a severe hemorrhagic tendency. The graft damage 
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hepatic vein. The range of  the graft/recipient weight ra-
tios was 0.74-4.58. Normal findings for histopathological 
analyses of  biopsy specimens during the donor operation 
were confirmed in all cases. The mean operative time was 
690.7 ± 150.0 min (range, 480-873 min) and the mean 
blood loss was 4180.0 ± 2843.3 mL (range, 370-7700 mL). 
The mean cold ischemic time, warm ischemic time and anhe-
patic phase were 49.4 ± 18.9 min (range, 27-77 min), 63.0 
± 32.9 min (range, 40-133 min) and 150 ± 76.6 min (range, 
51-267 min), respectively. All the recipients received blood 
transfusions of  a red cell concentrate and fresh-frozen 
plasma (FFP) during LDLT, and two recipients received a 
PLT transfusion. The patient profiles are shown in Table 1.
Immunosuppression 
Immunosuppression after LDLT was started with tacrolimus 
and methylprednisolone. The trough level of  tacrolimus 
was maintained at 8-15 ng/mL during the early postop-
erative period, based on the clinical findings in each case. 
Calcineurin inhibitors (CNIs) were converted to cyclo-
sporin A from tacrolimus at postoperative day (POD) 
15 in one case. Methylprednisolone was given intrave-
nously (1 mg/kg) once daily from POD 1 to POD 3 
followed by 0.5 mg/kg once daily for the next three days. 
On POD 7, 0.3 mg/kg of  methylprednisolone was given 
intravenously. Steroid administration was switched to oral 
prednisolone 0.3 mg/kg once daily on POD 8. This dose 
was reduced to 0.1 mg/kg at one month after LDLT. We 
had already overcome ABO-incompatibility in LDLT, and 
our regimens for these recipients, including heparin usage, 
were described previously[23,24].
The exclusion of other diseases
To exclude other diseases, such as humoral rejection (HR), 
hematological diseases, heparin-induced thrombocytopenia 
and autoimmune diseases, detailed examinations, such as 
bone-marrow puncture, liver needle biopsy, immunological 
assays and measurements of  anti-platelet factor 4/heparin 
Abs and anti-PLT autoantibodies were performed. 
Measurements of individual variables
In our institution, laboratory examinations were routine-
ly performed at least every 8-12 h in all recipients during 
the early postoperative period after LDLT and in critical 
LDLT recipients. The appearances of  fragmentation of  
Table 1  Recipient profiles
Recipients ABO1 TMALD2 Clinical courses after TMALD PE/ET3 Additional surgery4 Outcome
Pediatric Incompatible 21 Herpes simplex sepsis   0 None Alive
Pediatric Incompatible   6 Pneumonitis   4 None Alive
Adult Identical 14 Hepatic encephalopathy, intraperitoneal bleeding   9 Surgical hemostasis (16) Dead
Adult Incompatible   9 Hepatic encephalopathy, brain edema  gastroesophageal  varices rupt-
ure, intrathoracic intraperitoneal, bleeding sepsis, aspergillus infection 
  8 Surgical hemostasis (21) 
Re-transplantation (22)
Dead
Adult Compatible   4 Acute respiratory distress, syndrome intraperitoneal bleeding   5 None Dead
Adult Compatible 10 Intraperitoneal bleeding   3 Surgical hemostasis Dead
Adult Compatible 14 Hepatic arterial thrombosis  10 None Dead
1ABO blood group; 2The definite diagnosis of thrombotic microangiopathy like disorder (TMALD) [postoperative day (POD)]; 3The frequency of repeated 
plasma exchange/exchange transfusion (PE/ET) (Number of times); 4 Additional surgery for the complications (POD).
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score was estimated according to established guidelines[34], 
and was calculated as the total of  points of  the follow-
ing parenchymal features: hepatocyte ballooning (0 point 
= no, 1 = yes), hepatocyte necrosis (0 = none, 1 = small 
foci, 2 = confluent areas, 3 = bridging necrosis), conges-
tion (0 = no, 1 = yes), microvesicular fat (0 = none, 1 = 
1/3 hepatocytes, 2 = between 1/3 and 2/3 hepatocytes, 3 
= 2/3 hepatocytes), neutrophil aggregate (0 = none, 1 = 
minimal, 2 = moderate, 3 = extensive), and cholestasis (0 
= none, 1 = mild, 2 = moderate, 3 = severe).
Statistical analysis
The results are expressed as the mean ± SD. The differ-
ences between unpaired continuous or discontinuous data 
between two groups were analyzed by Student’s t-test. 
Survival rates were calculated by the Kaplan-Meier meth-
od, and the log-rank test was used for between-group 
comparisons. All calculations were performed using SPSS 
Software Version 16.0 (SPSS Inc., Chicago, IL 60606, 
USA). Differences with P values of  < 0.05 were consid-
ered to be statistically significant.
Ethical approval 
The protocol of  this study was approved by the Ethics 
Review Committee for Clinical Studies of  Kyoto Univer-
sity Graduate School of  Medicine.
RESULTS
TMALD onset after LDLT
TMALD was confirmed in seven cases, and the frequen-
cy in our institution was 3.4%. The definite diagnoses 
were reached at a mean time point of  POD 11.1 ± 5.7 
(range, 4-21 d). 
Clinical courses after TMALD and outcomes in TMALD 
patients
Five adult recipients clearly showed prolonged jaundice 
after TMALD [T-BIL peak, 38.9 ± 11.2 mg/dL (range, 
21.0-51.0 mg/dL)]. Four of  these five cases suffered 
massive bleeding because of  a hemorrhagic tendency 
in TMALD, and surgical hemostasis was emergently re-
quired in three cases. Thrombosis in the hepatic blood 
flow occurred after TMALD in one of  the five cases. 
Consequently, these five cases fell into graft loss after 
TMALD, and two of  the five recipients suffered hepatic 
encephalopathy. The details of  the clinical courses are 
shown in Table 1.
On the other hand, two pediatric recipients (ABO-in-
compatible combinations) showed good responses to the 
treatments for TMALD, and recovered from their severe 
graft damage (Table 1). 
In comparisons of  the survival rates, the TMALD 
patients clearly showed poor outcomes compared with 
the other patients who underwent LDLT during the same 
period in our institution (Figure 1A).
Critical events occurred after TMALD in five recipi-
ents and their clinical conditions tended to become worse 
despite the intensive treatments (Table 1). All of  these five 
recipients with TMALD finally died despite intensive treat-
ments (Figure 1B), and their mean survival time after the 
TMALD diagnosis was only 70 ± 63 d (range, 5-161 d). Al-
though one of  the five patients underwent a re-transplanta-
tion because of  graft loss, she also finally died (Table 1).
The values of diagnostic early markers and important 
signs
The fragmentation of  red cells was obviously detected in 
all cases. The haptoglobin level was also decreased to < 
5.0 mg/dL in all cases. MHMs were observed in five patients. 
The mean lowest value of  the PLT counts was 1.2 ± 5.5 × 
104/mm3 (range, 0.6-2.1 × 104/mm3) while that of  HB was 
6.61 ± 0.68 g/dL (range, 5.9-7.6 g/dL). The mean peak 
value of  the LDH level was 1202.3 ± 603.9 IU/L (range, 
518-2089 IU/L). The PT-INR value was prolonged to 
> 1.5 in only one case at the time of  a definite diagnosis, 
although the mean value for the most prolonged PT-INR 
after TMALD was 2.66 ± 1.85 (range, 1.22-5.64).















TMALD (n  = 7)
P  < 0.0001
Other recipients (n = 199)A
Time after LDLT (d)
Figure 1  Outcomes of thrombotic microangiopathy like disorder after living-donor liver transplantation. A: The seven thrombotic microangiopathy like disorder 
(TMALD) patients clearly showed a poor prognosis compared with the other 199 patients (P < 0.0001). TMALD after living-donor liver transplantation (LDLT) therefore 
had a negative impact upon the LDLT outcomes. A total of 206 LDLT recipients at Kyoto University Hospital (from April 2006 to March 2009) were evaluated; B: The 
thrombotic microangiopathy patients showed a poor prognosis despite intensive treatments after the diagnosis of TMALD. The open circles represent two recipients 
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Changes over time in important indicators for TMA
In two cases, the PLT counts before TMA onset were 
continuously < 5.0 × 104/mm3. Progressive decreases of  
> 3.0 × 104/mm3 within 24 h were considered to be the 
time points of  fulfilling the TMALD criteria in these cas-
es. Although MHMs were not necessarily observed in all 
cases, MHMs surprisingly appeared at the early phase of  
TMALD onset after LDLT, as well as FCR (Figure 2). In 
each case, elevated LDH levels proved decisive for making 
a diagnosis of  TMALD, although their appearances were 
mostly late, similar to the case for HB (Figure 2).
Absolute values of vWF and ADAMTS-13 and the vWF/
ADAMTS-13 ratio
In two cases, the vWF levels were within the normal range. 
The mean absolute value of  vWF was 306.6% ± 212.0% 
(range, 135%-723%) (Figure 3A). The ADAMTS-13 level 
also revealed no abnormalities in one case. The mean ab-
solute value of  ADAMTS-13 was 31.1% ± 24.3% (range, 
10%-75%) (Figure 3B). Therefore, the degrees of  altera-
tions in these absolute values did not seem to precisely 
reflect the TMALD outcomes after LDLT (Figure 3).
On the contrary, from the viewpoint of  an imbalance 
between vWF and ADAMTS-13, the ratio of  vWF/AD-
AMTS-13 strictly revealed the abnormalities in all of  the 
TMALD recipients after LDLT (Figure 4). The mean val-
ue for the vWF/ADAMTS-13 ratio was 11.0 ± 2.4 (range, 
7.8-14.6).
Inhibitors of ADAMTS-13
Qualitative analysis of  anti-ADAMTS-13 Abs produced 
negative results in all cases. Even in the quantitative de-
terminations, only two cases showed subtle elevations 
at approximately the cut-off  level, although some TMA 
patients in the hematological field in our hospital showed 
obvious elevation of  anti-ADAMTS-13 Abs.
Repeated PE/ET
Intensive care procedures for secondary complications, 
such as continuous hemodiafiltration for renal failure, respi-
ratory control for pulmonary dysfunction and intravenous 
administration of  antibiotics for sepsis, were performed in 
each case based on real-time estimations of  their physical 
conditions, if  necessary. 
PE/ET (FFP 80-100 mL/kg per day) were repeated 
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-5              -4              -3              -2              -1               0
P  < 0.0005
P  < 0.001
NS
P  < 0.005
 FRC (n = 7)
 MHM (n = 5)
 PLT (n  = 7)
 HB (n  = 7)
 LDH (n = 7)
Figure 2  Temporal changes in important markers and signs for throm-
botic microangiopathy. The statistical significances of the differences in each 
factor in comparison with the time points for lactate dehydrogenase (LDH) are 
shown. Note that although microhemorrhagic macules (MHMs) were only ob-
served in five of the seven cases (71.4%), the MHMs unexpectedly appeared at 
the early phase of thrombotic microangiopathy like disorder (TMALD) onset af-
ter living-donor liver transplantation, as well as fragmentation of red cells (FRC). 
In each case, the LDH levels proved decisive for making a diagnosis of TMALD, 
while the appearance of sufficient elevations of the LDH level were mostly late, 
similar to the case for hemoglobin (HB). PLT: Primary platelet.
Figure 3  Absolute values of von willebrand factor and a disintegrin-like 
domain and metalloproteinase with thrombospondin type 1 motifs-13. A The 
mean absolute value of von Willebrand factor (WF) was 306.6% ± 212.0% (range, 
135%-723%), and the vWF levels were within the normal range in two cases. The 
shaded area represents the normal range of vWF. The open circles represent 
two recipients who were successfully treated, and the closed circles represent 
five recipients who finally died; B The mean absolute value of a disintegrin-like 
domain and metalloproteinase with thrombospondin type 1 motifs (ADAMTS)-13 
was 31.1% ± 24.3% (range, 10%-75%), and the level of ADAMTS-13 was within 
the normal range in one case. The shaded area represents the normal range of 
ADAMTS-13. The open circles represent two recipients who were successfully 
treated, and the closed circles represent five recipients who finally died. Con-
sequently, the degrees of abnormalities in the absolute values of both vWF and 
ADAMTS-13 did not seem to precisely reflect the thrombotic microangiopathy like 






























Figure 4  Balance between von willebrand factor and a disintegrin-like 
domain and metalloproteinase with thrombospondin type 1 motifs-13. 
From the viewpoint of an imbalance between von Willebrand factor (vWF) and a 
disintegrin-like domain and metalloproteinase with thrombospondin type 1 motifs 
(ADAMTS)-13, the ratio of vWF/ADAMTS-13 strictly revealed the abnormalities 
in all thrombotic microangiopathy like disorder (TMALD) recipients after living-
donor liver transplantation (LDLT). The shaded area represents the normal range. 
The mean value of the vWF/ADAMTS-13 ratio was 11.0 ± 2.4 (range, 7.8-14.6). 
The open circles represent two recipients who were successfully treated, and the 
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Time before making the definite diagnosis and starting the intensive treatments (d)
as the standard therapy for TMALD in six cases immedi-
ately after making a definite diagnosis of  TMALD. The 
mean number of  times of  repeated PE/ET was 6.5 ± 2.9 
(range, 3-10). Repeated PE therapy was not introduced 
in only one patient who successfully recovered from 
TMALD. It has been suggested since that repeated PE 
for the liver failure before LDLT can cause a recurrence 
of  herpes simplex infection after LDLT because of  the 
depletion of  antigen-specific Abs by PE and the non-
specific immunosuppression after LDLT. 
Graft parenchymal damage 
Histopathological analysis of  LNB specimens clearly re-
vealed that the five recipients who had poor outcomes 
suffered graft loss after TMALD. 
The mean graft damage scores before and after TMALD 
treatments in all patients were 8.9 ± 2.2 points (range, 
5-12 points) and 8.7 ± 4.0 points (range, 2-12 points), re-
spectively (Figure 5). 
In comparisons of  the histopathological findings 
before and after TMALD treatments, the results clearly 
demonstrated that the five recipients who had poor 
outcomes still showed severe graft parenchymal dam-
age despite of  repeated PE [mean graft damage score 
after TMALD treatments, 8.8 ± 2.6 points (range, 5-12 
points)], although the two surviving recipients recovered 
from their graft parenchymal damage after repeated ET 
(four times) or no PE/ET treatment. The graft dam-
age scores after TMALD treatments in the successfully 
treated recipients decreased to two or four points. 
DISCUSSION
Although the specific mechanism remains unknown, previ-
ous reports have documented that CNIs and infections, 
including cytomegalovirus (CMV) and HCV infections, 
may be possible causes of  TMA after LT[2,17,35-39]. Despite 
the fact that our institution is a major transplant center 
in Japan, the frequency of  TMA in our institution may 
be slightly lower than those in previous reports[16,18]. A 
possible explanation for this is the well-controlled condi-
tions aimed at preventing CMV and HCV infections af-
ter LDLT in our institution[40,41]. In particular, our clinical 
strategy brings about excellent long-term outcomes after 
LDLT for recipients with HCV[40], and the frequency of  
TMALD in such recipients is 3.2% (2 TMALD cases 
among 62 HCV patients after LDLT) in our institution. 
Paradoxically, uncontrolled HCV infection may be a trig-
ger of  TMA onset as previously described[2,42]. TMA oc-
curs as a long-term complication after LT by association 
with viral infections[2], whereas our patients presented 
with TMALD during the early postoperative period. 
One of  the possible explanations is the good control 
of  viral infections as described above, although we are 
sometimes troubled by Epstein-Barr virus infections, in-
cluding long-term complications of  post-transplantation 
lymphoproliferative disorders[43]. Regarding CNIs, our 
results that CNIs were used in all cases (tacrolimus was 
switched to cyclosporin A in 1 case) reveal an undeni-
able possibility of  CNI effects, as previously docu-
mented[17,35,36,39]. We also cannot negate the possibility 
that CNI introduction caused TMALD during the early 
postoperative period in our cases. However, we consider 
that complete CNI-free LDLT for preventing TMA is 
a distant ideal, since CNIs are key immunosuppressants 
for LDLT during this period[15,44].
The mortality of  TMA patients without effective 
treatments can be as high as 90%[1,16], and 10%-20% 
of  TMA patients still die even after PE/ET[13,45]. The 
outcomes of  TMALD patients are truly poor in our 
institution. Serious problems, such as massive bleeding, 
vascular thrombosis and organ failures, actually ap-
peared in these recipients because of  PLT consumption 
and microvascular occlusion mediated by TMALD. Five 
TMALD patients died without long survival times de-
spite receiving continuous intensive treatments including 
re-transplantation for graft loss. Our own results indicate 
that further improvements in clinical strategies, including 
diagnostic methods and effective treatments based on 
the TMA mechanism after LDLT, are still needed.
Currently, the criteria for TMA are established as 
described above. We still do not have any experience of  
patients who strictly fulfilled all of  the TMA criteria. 
Therefore, we consider that our patients were TMALD 
rather than TMA. However, we think that our recipients 
are homogeneously the same as other TMA patients in 
their clinical events. Based on our results in assays for 
TMA diagnosis, TMA recipients after LT may not be 
considered in the same manner as congenital or autoim-
mune TMA patients purely in the hematological field, 
when making a definite diagnosis. Inherently, TMA in-
volves microvascular occlusion and unusually large vWF 
multimers are present at its inception[1,7]. Although we 

























Figure 5  Graft parenchymal damage before and after thrombotic microan-
giopathy like disorder treatments. The mean graft damage scores before and 
after thrombotic microangiopathy like disorder (TMALD) treatments in all pa-
tients were 8.9 ± 2.2 points (range, 5-12 points) and 8.7 ± 4.0 points (range, 2-12 
points), respectively. In comparisons of the histopathological findings before 
and after TMALD treatments, the graft damage scores clearly demonstrated 
that five recipients who had poor outcomes (closed circles) showed no improve-
ments despite repeated plasma exchange (PE). The mean graft damage score 
after TMALD treatments in these five recipients was 8.8 ± 2.6 points (range, 5-12 
points). On the other hand, the two surviving recipients (open circles) recovered 
from their graft parenchymal damage. The graft damage scores after TMALD 
treatments in these two recipients were two and four points.
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initially focused on vWF and ADAMTS-13, similar to 
previous studies[2-5,8,9,14], we found that these absolute val-
ues were not necessarily reliable for the confirmation of  
TMA in LDLT recipients. Our results revealed only ten-
dencies toward high vWF and low ADAMTS-13, while a 
few cases showed normal absolute values. However, the 
balance between vWF and ADAMTS-13 was clearly bro-
ken down. We suggest that this imbalance is a true entity 
in TMA after LDLT, and that evaluation of  the vWF/
ADAMTS-13 ratio is more suitable after LDLT to estab-
lish the patient’s condition and achieve a precise diagno-
sis of  TMA. Since a precise diagnosis is always required 
in order to administer appropriate treatments[2,14,15], we 
suggest that this variable is one of  the keys for improv-
ing the TMALD outcomes after LDLT.
Immunologically and pharmaceutically, numerous 
unpreventable influences exist in LDLT recipients. The 
phenomena of  microvascular occlusive disorders ac-
companied by endothelial damage, PLT aggregation and 
hemolysis will be observed for other reasons, such as 
HR. On making a diagnosis of  TMA after LDLT, many 
examinations including hematological, immunological 
and histopathological assays are therefore required to 
rule out other possible reasons, such as HR, sepsis and 
autoantibodies as well as HIT and drug-induced dis-
orders[2,14]. Therefore, reaching a definite diagnosis of  
TMA usually requires many considerations and much 
time. Actually, in our results, we retrospectively consid-
ered that TMALD onsets were earlier rather than at the 
point of  diagnosis and/or treatment induction. We sug-
gest that although the LDH level has a specific sensitivity 
for TMA/TMALD this variable will not work as an early 
marker for TMA/TMALD. Decreases in PLT counts 
can cause serious problems which sometimes require ad-
ditional surgery. FRC and PLT decreases were observed 
at earlier points, and unexpectedly, MHMs were also 
reliable as an early sign of  TMALD after LDLT if  they 
appeared. A possible explanation is the time-lag between 
an initial high shear stress and the resultant microvascu-
lar occlusion[6,7]. Ironically, transplant surgeons cannot 
decide actual treatments based on FRC, MHMs and PLT 
decreases even with earlier appearances, while TMA ba-
sically contraindicates a PLT transfusion. Although the 
changes over time in vWF and ADAMTS-13 could not 
be estimated in these patients because of  cost-saving 
reasons, we hypothesize that the ratio of  vWF/AD-
AMTS-13 is the earliest marker after LDLT for ruling 
out TMA and deciding appropriate treatments from the 
viewpoint of  an essential cause of  TMA.
Basically, the treatments must be chosen based on 
each cause of  TMA, i.e. the lack of  ADAMTS-13 and/
or the inhibition of  ADAMTS-13 via specific Abs[2,3,8,9]. 
We suggest that adequate therapies, i.e. PE/ET for 
ADAMTS-13 replenishment or additional treatments 
against inhibitory Abs, must be decided according to 
each cause of  TMA/TMALD. The PE/ET has effects 
on both replenishment of  ADAMTS-13 and depletion 
of  inhibitory Abs against ADAMTS-13. Therefore, 
PE/ET (80-100 mL/kg per day) is widely considered 
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as the standard therapy for TMA[13,15,20-22]. As described 
above, the essence of  TMA after LDLT is an imbalance 
between vWF and ADAMTS-13, and we expect that 
PE/ET will have a sufficient effect from the viewpoint 
of  the replenishment of  ADAMTS-13. However, the 
five TMALD patients who finally died revealed that 
the graft loss caused by TMALD resulted in poor out-
comes, even in a re-transplanted case, and that graft 
parenchymal damage became worse one-sidedly despite 
the intensive treatments. On the contrary, the other 
two TMALD patients were successfully treated, even 
though the treatment in one case excluded PE/ET. The 
graft damage caused by TMALD exhibited sufficient re-
sponses to the administered treatments in these success-
fully treated patients. Our results indicate that further 
improvements for TMALD after LDLT are truly re-
quired. We suggest that PE/ET itself  has an anticipated 
efficacy in TMALD patients who lack ADAMTS-13[3,8]. 
Furthermore, optimal timing of  the PE/ET induction 
according to the TMALD onset can improve the out-
comes in these patients, even though the same treatment 
is performed[2,13-15,45]. The morbidity and mortality may 
increase if  we hesitate to introduce the therapy until the 
criteria for TMA are completely fulfilled. We therefore 
suggest that earlier induction will improve the outcomes 
in ADAMTS-13-deficient patients when TMALD is 
suspected after LDLT based on early markers or an 
imbalance of  the vWF/ADAMTS-13 ratio. Since our 
results showed that successful treatments are difficult 
once the TMA criteria are completely fulfilled, we con-
sider that some data and/or signs accompanied by a 
PLT decrease are sufficient for PE/ET induction after 
LDLT, e.g. FCR, MHMs and a discrepancy of  LDH 
elevation (even under the criteria) compared with other 
transaminases. On the other hand, PE/ET also has a 
benefit in TMALD patients accompanied by inhibitors 
from the viewpoint of  Ab depletion[2,9,15]. However, our 
results for the TMALD patients who died might sustain 
the previous opinion that PE/ET has a limited usage for 
the depletion of  specific Abs[15,46], and the actual results 
of  poor outcomes oblige us to challenge some other 
therapies for TMALD patients after LDLT. Although 
we have no experience of  Ab-positive TMA after LDLT, 
we now take anti-CD20 monoclonal Ab or intravenous 
high-dose IgG administration under consideration, if  re-
peated PE/ET has insufficient effects on TMA progress. 
Previous investigators suggested the diagnostic 
and therapeutic advices for TMA, and previous re-
ports which focused TMA after LT were summarized 
in Table 2[2,14,15,37-39,47,48]. In our institution, the outcomes 
of  TMALD recipients were poor despite the intensive 
treatments, especially in adult LDLT recipients. Previous 
researchers investigated the risk factors for TMA after 
LT[15,39], and Nishi et al[15] suggested that the onset POD, 
the value of  urea nitrogen and the level of  albumin were 
important for TMA outcomes after LDLT. In our in-
stitution, the levels of  urea nitrogen were not measured 
routinely. A possible explanation for the poor outcomes 
of  TMALD after LDLT in our institution was the early 
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postoperative onset of  TMALD within 30 d after LDLT 
(Table 1), though the albumin levels showed no statistical 
differences between groups. Current therapeutic strategies 
were still not enough, and we therefore speculated that 
an earlier induction of  adequate treatments based on the 
early markers may improve the prognosis of  TMALD 
after LDLT. We considered that the earlier recognition 
of  TMALD and the earlier induction of  treatments even 
under a suspicion of  TMALD are crucial for LDLT re-
cipients with TMALD. 
TMA/TMALD stands as an infrequent but life-threat-
ening complication in the LT field. Although retrans-
plantation may seem to be a therapeutic option, this is 
strictly limited from the viewpoints of  donor shortage 
and donor safety. We suggest that adequate therapies, i.e. 
PE/ET for ADAMTS-13 replenishment or additional 
treatments against inhibitory Abs, must be decided ac-
cording to each cause of  TMA/TMALD. We conclude 
that the optimal induction of  these therapies based on 
earlier or reliable markers and the establishment of  more 
advanced therapeutic strategies confers a large advantage 
for TMA/TMALD patients after LDLT and consequently 
improves LT outcomes. 
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